QH103 Cell Injection for treating relapsed B-cell leukemia

A Dose-escalation Clinical Study of QH103 Cell Injection (CD19 CAR-γδT Cell Injection) in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL).

This study is testing a new cell injection treatment for people with relapsed B-cell leukemia to see how safe it is and what the highest dose they can handle is.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Ages: 14 Years and up
• Sex: All
• Sponsor: Anhui Provincial Hospital (Government)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Hefei, Anhui)
• Trial ID: NCT06056752 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety and tolerability of QH103 Cell Injection in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). It is a single-arm, single-center, interventional study that focuses on determining the maximum tolerated dose and any dose-limiting toxicities associated with the treatment. Patients will receive QH103 Cell Injection along with Fludarabine and Cyclophosphamide as part of the treatment regimen.

Who should consider this trial

Good fit: Ideal candidates include patients aged 14 and older with relapsed or refractory CD19-positive B-ALL who have not responded to standard treatments.

Not a fit: Patients with extramedullary disease only or those with a poor expected survival time of less than 3 months may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with difficult-to-treat B-cell acute lymphoblastic leukemia.

How similar studies have performed: Other studies using CAR T-cell therapies have shown promising results in treating similar conditions, indicating potential for success with this approach.

Eligibility criteria

Inclusion Criteria:

1. Age ≥14 years, gender is not limited;
2. Patients with clinically diagnosed relapsed/refractory B-ALL (except those presenting with extramedullary disease only), including any of the following:

   1. Failure to obtain CR after 2 cycles of standard chemotherapy;
   2. First induction of CR, but duration of CR is ≤12 months;
   3. Relapsed/refractory B-ALL that has failed to respond to the first or multiple salvage treatments;
   4. Relapse after hematopoietic stem cell transplantation, including hematological relapse and positive micro residual disease (MRD).
3. Cytological or histological confirmation of tumor cell immunophenotyping as CD19 positive;
4. Bone marrow with a ratio of ≥5% primitive/naïve lymphocytes (morphology);
5. Expected survival time of more than 3 months;
6. Eastern Cooperative Oncology Group (ECOG) score of 0-2;
7. Vital organ function meets the following requirements: left ventricular ejection fraction ≥50% on echocardiography; serum creatinine≤1.5 × upper limit of normal range (ULN); glutamine aminotransferase, aspartate aminotransferase ≤3 times ULN, total bilirubin ≤1.5 times ULN;
8. Pregnancy tests for women of childbearing age should be negative, and both men and women should agree to use effective contraception during treatment and for the following 1 year.
9. Toxicity of prior antitumor therapy ≤ grade 1 (according to CTCAE version 5.0) or acceptable inclusion/exclusion criteria level.
10. No significant hereditary disease;
11. Be able to understand the requirements and matters of the trial and be willing to participate in the clinical study as required;
12. Sign the trial informed consent form.

Exclusion Criteria:

1. with uncontrolled active central nervous system leukemia (CNSL) or a history of epilepsy, cerebrovascular disease
2. Pregnant or lactating women, or those who do not consent to the use of the drug during and within 1 year after treatment;
3. Other malignant tumors not in remission;
4. with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy;
5. Patients who have received immune cell therapy within 6 months prior to enrollment and donor lymphocyte infusion within 6 weeks prior to enrollment.
6. Patients with confirmed positive serum anti-FMC63 and DSA reactions;
7. Patients who have participated in other clinical trials within 4 weeks prior to enrollment;
8. Uncontrolled infectious or other serious diseases, including but not limited to infections (Human Immunodeficiency Virus, acute or chronic active hepatitis B or hepatitis C), congestive heart failure, unstable angina pectoris cardiac arrhythmias, or conditions that the attending physician considers to be an unpredictable risk;
9. Uncontrollable plasma fluid, such as large pleural effusions or ascites;
10. History of stroke or intracranial hemorrhage within 3 months prior to enrollment;
11. Major surgery or trauma within 28 days prior to enrollment, or major side effects from which you have not recovered;
12. History of allergy to any of the ingredients in the cellular product;
13. Inability to understand or unwillingness to sign the informed consent form;
14. Other reasons deemed by the investigator to be unsuitable for the clinical trial.

Where this trial is running

Hefei, Anhui

• Anhui Provincial Hospital — Hefei, Anhui, China (Recruiting)

Study contacts

• Principal investigator: Xiaoyu Zhu, Ph.D — Director of Hematology Department, Anhui Provincial Hospital
• Study coordinator: Xiaoyu Zhu, Ph.D

Conditions B-cell Acute Lymphoblastic Leukemia; B-ALL; Allogenic CAR-γδT Cell; CD19; cell therapy